A Pharmaceutical Executive on Trump’s Tariff Strategy
Earlier this month, President Donald Trump announced the U.S. would impose up to a 200% tariff on imported pharmaceuticals, though he would give them up to a year and a half before fully implementing the tariffs. Trump’s goal is to bring more manufacturing to the United States, but one pharmaceutical CEO, Richard Saynor of Sandoz, says there is little incentive to build in the U.S. Jessica Mendoza hosts.
Further Listening:
- Why Trump Pushed His Tariff Deadline
- Inside the Surprise U.S.-China Trade Deal
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More description
Earlier this month, President Donald Trump announced the U.S. would impose up to a 200% tariff on imported pharmaceuticals, though he would give them up to a year and a half before fully implementing the tariffs. Trump’s goal is to bring more manufacturing to the United States, but one pharmaceutical CEO, Richard Saynor of Sandoz, says there is little incentive to build in the U.S. Jessica Mendoza hosts.
Further Listening:
- Why Trump Pushed His Tariff Deadline
- Inside the Surprise U.S.-China Trade Deal
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.